Literature DB >> 23298236

Novel P2 tris-tetrahydrofuran group in antiviral compound 1 (GRL-0519) fills the S2 binding pocket of selected mutants of HIV-1 protease.

Hongmei Zhang1, Yuan-Fang Wang, Chen-Hsiang Shen, Johnson Agniswamy, Kalapala Venkateswara Rao, Chun-Xiao Xu, Arun K Ghosh, Robert W Harrison, Irene T Weber.   

Abstract

GRL-0519 (1) is a potent antiviral inhibitor of HIV-1 protease (PR) possessing tris-tetrahydrofuran (tris-THF) at P2. The high resolution X-ray crystal structures of inhibitor 1 in complexes with single substitution mutants PR(R8Q), PR(D30N), PR(I50V), PR(I54M), and PR(V82A) were analyzed in relation to kinetic data. The smaller valine side chain in PR(I50V) eliminated hydrophobic interactions with inhibitor and the other subunit consistent with 60-fold worse inhibition. Asn30 in PR(D30N) showed altered interactions with neighboring residues and 18-fold worse inhibition. Mutations V82A and I54M showed compensating structural changes consistent with 6-7-fold lower inhibition. Gln8 in PR(R8Q) replaced the ionic interactions of wild type Arg8 with hydrogen bond interactions without changing the inhibition significantly. The carbonyl oxygen of Gly48 showed two alternative conformations in all structures likely due to the snug fit of the large tris-THF group in the S2 subsite in agreement with high antiviral efficacy of 1 on resistant virus.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23298236      PMCID: PMC3574189          DOI: 10.1021/jm301519z

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  38 in total

1.  Potent antiviral HIV-1 protease inhibitor GRL-02031 adapts to the structures of drug resistant mutants with its P1'-pyrrolidinone ring.

Authors:  Yu-Chung E Chang; XiaXia Yu; Ying Zhang; Yunfeng Tie; Yuan-Fang Wang; Sofiya Yashchuk; Arun K Ghosh; Robert W Harrison; Irene T Weber
Journal:  J Med Chem       Date:  2012-03-22       Impact factor: 7.446

2.  Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site.

Authors:  Bhuvaneshwari Mahalingam; Yuan-Fang Wang; Peter I Boross; Jozsef Tozser; John M Louis; Robert W Harrison; Irene T Weber
Journal:  Eur J Biochem       Date:  2004-04

Review 3.  Retroviral proteinases.

Authors:  S Oroszlan; R B Luftig
Journal:  Curr Top Microbiol Immunol       Date:  1990       Impact factor: 4.291

4.  Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir.

Authors:  Fengling Liu; Andrey Y Kovalevsky; Yunfeng Tie; Arun K Ghosh; Robert W Harrison; Irene T Weber
Journal:  J Mol Biol       Date:  2008-07-01       Impact factor: 5.469

5.  Influence of flanking sequences on the dimer stability of human immunodeficiency virus type 1 protease.

Authors:  E M Wondrak; J M Louis
Journal:  Biochemistry       Date:  1996-10-01       Impact factor: 3.162

6.  Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere.

Authors:  A K Ghosh; J F Kincaid; W Cho; D E Walters; K Krishnan; K A Hussain; Y Koo; H Cho; C Rudall; L Holland; J Buthod
Journal:  Bioorg Med Chem Lett       Date:  1998-03-17       Impact factor: 2.823

7.  Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S.

Authors:  Fengling Liu; Peter I Boross; Yuan-Fang Wang; Jozsef Tozser; John M Louis; Robert W Harrison; Irene T Weber
Journal:  J Mol Biol       Date:  2005-10-21       Impact factor: 5.469

8.  Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.

Authors:  Milan Kozísek; Jenelle Bray; Pavlína Rezácová; Klára Sasková; Jirí Brynda; Jana Pokorná; Fabrizio Mammano; Lubomír Rulísek; Jan Konvalinka
Journal:  J Mol Biol       Date:  2007-10-03       Impact factor: 5.469

Review 9.  Nelfinavir. A review of its therapeutic efficacy in HIV infection.

Authors:  B Jarvis; D Faulds
Journal:  Drugs       Date:  1998-07       Impact factor: 9.546

10.  HIV-1 Protease: Structural Perspectives on Drug Resistance.

Authors:  Irene T Weber; Johnson Agniswamy
Journal:  Viruses       Date:  2009-12-03       Impact factor: 5.048

View more
  17 in total

Review 1.  Highly resistant HIV-1 proteases and strategies for their inhibition.

Authors:  Irene T Weber; Daniel W Kneller; Andres Wong-Sam
Journal:  Future Med Chem       Date:  2015       Impact factor: 3.808

2.  Enantioselective Synthesis of Dioxatriquinane Structural Motifs for HIV-1 Protease Inhibitors Using a Cascade Radical Cyclization.

Authors:  Arun K Ghosh; Chun-Xiao Xu; Heather L Osswald
Journal:  Tetrahedron Lett       Date:  2015-06-03       Impact factor: 2.415

3.  Design of new potent HTLV-1 protease inhibitors: in silico study.

Authors:  Mitra Kheirabadi; Javad Maleki; Safieh Soufian; Samaneh Hosseini
Journal:  Mol Biol Res Commun       Date:  2016-03

4.  Structure-based design of potent HIV-1 protease inhibitors with modified P1-biphenyl ligands: synthesis, biological evaluation, and enzyme-inhibitor X-ray structural studies.

Authors:  Arun K Ghosh; Xufen Yu; Heather L Osswald; Johnson Agniswamy; Yuan-Fang Wang; Masayuki Amano; Irene T Weber; Hiroaki Mitsuya
Journal:  J Med Chem       Date:  2015-06-24       Impact factor: 7.446

5.  Structural studies of antiviral inhibitor with HIV-1 protease bearing drug resistant substitutions of V32I, I47V and V82I.

Authors:  Shrikant Pawar; Yuan-Fang Wang; Andres Wong-Sam; Johnson Agniswamy; Arun K Ghosh; Robert W Harrison; Irene T Weber
Journal:  Biochem Biophys Res Commun       Date:  2019-05-12       Impact factor: 3.575

6.  Beyond Members of the Flaviviridae Family, Sofosbuvir Also Inhibits Chikungunya Virus Replication.

Authors:  André C Ferreira; Patrícia A Reis; Caroline S de Freitas; Carolina Q Sacramento; Lucas Villas Bôas Hoelz; Mônica M Bastos; Mayara Mattos; Natasha Rocha; Isaclaudia Gomes de Azevedo Quintanilha; Carolina da Silva Gouveia Pedrosa; Leticia Rocha Quintino Souza; Erick Correia Loiola; Pablo Trindade; Yasmine Rangel Vieira; Giselle Barbosa-Lima; Hugo C de Castro Faria Neto; Nubia Boechat; Stevens K Rehen; Karin Brüning; Fernando A Bozza; Patrícia T Bozza; Thiago Moreno L Souza
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

7.  Extreme multidrug resistant HIV-1 protease with 20 mutations is resistant to novel protease inhibitors with P1'-pyrrolidinone or P2-tris-tetrahydrofuran.

Authors:  Johnson Agniswamy; Chen-Hsiang Shen; Yuan-Fang Wang; Arun K Ghosh; Kalapala Venkateswara Rao; Chun-Xiao Xu; Jane M Sayer; John M Louis; Irene T Weber
Journal:  J Med Chem       Date:  2013-05-01       Impact factor: 7.446

8.  Joint X-ray/neutron crystallographic study of HIV-1 protease with clinical inhibitor amprenavir: insights for drug design.

Authors:  Irene T Weber; Mary Jo Waltman; Marat Mustyakimov; Matthew P Blakeley; David A Keen; Arun K Ghosh; Paul Langan; Andrey Y Kovalevsky
Journal:  J Med Chem       Date:  2013-06-28       Impact factor: 7.446

9.  Probing Lipophilic Adamantyl Group as the P1-Ligand for HIV-1 Protease Inhibitors: Design, Synthesis, Protein X-ray Structural Studies, and Biological Evaluation.

Authors:  Arun K Ghosh; Heather L Osswald; Kristof Glauninger; Johnson Agniswamy; Yuan-Fang Wang; Hironori Hayashi; Manabu Aoki; Irene T Weber; Hiroaki Mitsuya
Journal:  J Med Chem       Date:  2016-07-07       Impact factor: 7.446

10.  Highly potent HIV-1 protease inhibitors with novel tricyclic P2 ligands: design, synthesis, and protein-ligand X-ray studies.

Authors:  Arun K Ghosh; Garth L Parham; Cuthbert D Martyr; Prasanth R Nyalapatla; Heather L Osswald; Johnson Agniswamy; Yuan-Fang Wang; Masayuki Amano; Irene T Weber; Hiroaki Mitsuya
Journal:  J Med Chem       Date:  2013-08-15       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.